Treatments
TL;DR: 14 FDA-approved drugs have labels that mention ovarian cancer in their indications. Grouped below by mechanism of action. This list gives you the vocabulary — your oncologist chooses a regimen based on your specific subtype, stage, biomarkers, and prior therapies.
Source: OpenFDA drug label API · last checked
Cost transparency
Drugs below have published Medicare Part B or Part D spending figures — what the federal government actually paid per beneficiary in 2023.
Figures are average Medicare spending per beneficiary. Out-of-pocket varies by insurance and manufacturer assistance. See all drug costs →
Drugs that activate or modify the immune system to attack cancer cells. Checkpoint inhibitors (targeting PD-1, PD-L1, CTLA-4) are the most common.
Programmed Death Receptor-1 Blocking Antibody [EPC] · Programmed Death Receptor-1-directed Antibody Interactions [MoA]
From the FDA label: 1 INDICATIONS AND USAGE KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric…
Endoglycosidase [EPC] · Programmed Death Receptor-1 Blocking Antibody [EPC]
From the FDA label: 1 INDICATIONS AND USAGE KEYTRUDA QLEX is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase, indicated: Melanoma for the treatment of adult patients with un…
Small-molecule drugs taken by mouth that block specific molecular pathways driving cancer growth (kinases, PARP, CDK4/6, etc.).
From the FDA label: 1 INDICATIONS AND USAGE AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with KRAS -mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy. This indication is approved und…
From the FDA label: 1 INDICATIONS AND USAGE ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a compl…
Poly(ADP-Ribose) Polymerase Inhibitor [EPC] · Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
From the FDA label: 1 INDICATIONS AND USAGE Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated adva…
From the FDA label: 1 INDICATIONS AND USAGE RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated recurrent epi…
Cytotoxic drugs that kill rapidly dividing cells. Includes platinums, taxanes, antimetabolites, alkylators, topoisomerase inhibitors, and anthracyclines.
Platinum-based Drug [EPC]
From the FDA label: 1 INDICATIONS AND USAGE Cisplatin for injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer ( 1.1 ) • Advanced ovarian cancer ( 1.2 ) • Advanced bladder cancer ( 1.3 ) 1.1 Advanced Testicular Cancer…
From the FDA label: 1 INDICATIONS AND USAGE Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: Ovarian cancer : After failure of platinum-based chemotherapy ( 1.1 ) AIDS-related Kaposi’s Sarcoma : After fail…
From the FDA label: 1 INDICATIONS AND USAGE Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer: After failure of platinum-based chemotherapy ( 1.1 ) • AIDS-related Kaposi’s Sarcoma: After fa…
From the FDA label: 1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-base…
From the FDA label: 1 INDICATIONS AND USAGE Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: • in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-ba…
From the FDA label: 1 INDICATIONS AND USAGE Topotecan Hydrochloride for injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a si…
Drugs whose pharmacologic class was not automatically classified into the groups above. Check the FDA label for mechanism details.
From the FDA label: 1 INDICATIONS AND USAGE ETHYOL is a cytoprotective agent indicated for: – reduction of cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. ( 1.1 ) – reduction of the incid…
From the FDA label: 1. INDICATIONS AND USAGE CYTALUX is indicated as an adjunct for intraoperative identification of: Malignant lesions in adult patients with ovarian cancer. Malignant and non-malignant pulmonary lesions in adult patients with known or suspect…
Disease foundations below have active funds covering ovarian cancer medications. Manufacturer patient-assistance programs are listed on each drug's cost page.
copay, premium, and deductible assistance for insured patients; fund availability varies by disease
https://www.healthwellfoundation.org/disease-funds/Funds open and close based on availability; check disease-funds page for current status
copay assistance for 20+ cancer types via disease-specific funds
https://www.panfoundation.org/find-disease-fund/Merging with Patient Advocate Foundation; unified 'TotalAssist' program launches 2026-07-01
direct copay / coinsurance assistance via disease-specific funds
https://copays.org/Merging with PAN Foundation; launching 'TotalAssist' 2026-07-01
copay assistance for chemotherapy and targeted treatment medications
https://www.cancercare.org/copayfoundationlimited financial assistance for transportation, home care, child care, and treatment-related costs
https://www.cancercare.org/financialTrials test new therapies before they are FDA-approved. Often a way to access tomorrow's drugs today.
Back to Ovarian Cancer hub →Stats, second opinions, NCI cancer centers, oncologists.
Understand biomarkers →Most targeted therapies require biomarker testing. Here's what you need to know.
Read your pathology report →Which drugs apply to you depends on what's in your pathology.